Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...4041424344454647484950...208209»
  • ||||||||||  HRS-7535 / Kailera Therapeutics
    Trial completion:  HRS-7535-202: Efficacy and Safety of HRS-7535 Tablets in Obese Subjects . (clinicaltrials.gov) -  Apr 14, 2025   
    P2,  N=235, Completed, 
    Moreover, the TRG was found to be significantly associated with imaging assessment; these two approaches can be combined and employed to predict the efficacy of neoadjuvant immuno-chemotherapy. Not yet recruiting --> Completed
  • ||||||||||  HRS-7535 / Kailera Therapeutics
    Enrollment closed, Enrollment change:  Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects (clinicaltrials.gov) -  Apr 10, 2025   
    P2,  N=81, Active, not recruiting, 
    Subsequent treatment with a combination of flumatinib and ruxolitinib was demonstrated to be safe and effective. N=180 --> 81 | Not yet recruiting --> Active, not recruiting
  • ||||||||||  SHR-1707 / Jiangsu Hengrui Pharma
    Enrollment closed, Trial primary completion date:  Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients. (clinicaltrials.gov) -  Apr 10, 2025   
    P1,  N=33, Active, not recruiting, 
    N=180 --> 81 | Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> May 2024
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Phase classification:  Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) -  Apr 9, 2025   
    P1,  N=20, Not yet recruiting, 
    A CT-based clinical-radiomics nomogram exhibits strong potential for predicting OS in advanced HCC patients undergoing TACE combined with camrelizumab and apatinib. Phase classification: P1/2 --> P1
  • ||||||||||  Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma, cyclosporine / Generic mfg.
    Journal:  The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia. (Pubmed Central) -  Apr 7, 2025   
    Collectively meaningful proteomic biomarkers are beneficial to evaluate the efficacy of immunotherapy, and these discovered biomarkers may be included in the scope of treatments' evaluation and improvement in future study. Old individuals are at a high risk of developing aplastic anemia, and immunosuppressive therapy (IST) based on anti-human T-lymphocyte immunoglobulin (ATG) and cyclosporine (CsA) is recommended for treating severe aplastic anemia (SAA)...Eltrombopag was administered at a dose of 75-150
  • ||||||||||  retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, Rybrevant (amivantamab-vmjw) / J&J, Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
    Review, Journal:  Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer. (Pubmed Central) -  Apr 7, 2025   
    Herein we present the structure, classification, and mechanism of action underlying bsAbs in NSCLC and introduce related clinical trials. Finally, we discuss challenges, potential solutions, and future prospects in the context of cancer treatment with bsAbs.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review. (Pubmed Central) -  Apr 7, 2025   
    He underwent multiple cycles of therapy, tolerating camrelizumab, nab-paclitaxel, and nedaplatin (200 mg of camrelizumab every 3 weeks) without adverse reactions in the first four cycles...The camrelizumab infusion was immediately halted, and the patient was treated with intravenous dexamethasone (10 mg) combined with intramuscular diphenhydramine, calcium gluconate, and 500 ml of normal saline; his blood pressure gradually increased to 110/80 mmHg within 10 minutes, and pruritic erythematous macules appeared on his skin, particularly on the upper limbs...The patient did not report significant discomfort. Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority.
  • ||||||||||  Zynyz (retifanlimab-dlwr) / Incyte, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Enrollment closed, Trial completion date, Trial primary completion date:  INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (clinicaltrials.gov) -  Apr 4, 2025   
    P2,  N=25, Active, not recruiting, 
    Although acute allergic reactions are relatively rare among immune-related adverse events, due to the widespread clinical application of camrelizumab, its potential for allergic reactions should be given high priority. Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  P2 data, Journal:  Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial. (Pubmed Central) -  Apr 3, 2025   
    P2
    The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo...After enrollment, patients received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab)...No external funding was received for this work. ClinicalTrials.gov: NCT05880927.